BioTuesdays

Tag - hepatitis B

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

Arbutus taking multi-faceted approach to HBV

Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with hepatitis B...

William Blair analyst discusses Hep B space

As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.